AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

AROA BIOSURGERY LIMITED Capital/Financing Update 2021

Aug 24, 2021

64426_rns_2021-08-24_919625a0-3f02-492f-835f-284318402367.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

ASX ANNOUNCEMENT/MEDIA RELEASE 25 August 2021

==> picture [113 x 52] intentionally omitted <==

SECTION 708A NOTICE

This notice is given by Aroa Biosurgery Limited ( Company ) under Section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act).

The Company hereby confirms that:

(a) it has today issued 340,957 fully paid ordinary shares at an issue price of $1.165 per share to eligible shareholders in relation to the Share Purchase Plan announced on 4 August 2021;
(b) the shares referred to in paragraph (a) above were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
(c) the Company is providing this notice under paragraph 5(e) of Section 708A of the Corporations Act;
(d) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:
(i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
(ii) Section 674 of the Corporations Act as it applies to the Company; and
(e) as at the date of this announcement, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act.

< ENDS >

Authorised on behalf of the Aroa Biosurgery Board of Directors by Jim McLean, Independent Chair.

About Aroa Biosurgery:

Aroa Biosurgery is a soft-tissue regeneration company that develops, manufactures, sells and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Committed to ‘unlocking regenerative healing for everybody’, its products are developed from the Company’s proprietary Endoform® technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. Clinically proven with peer reviewed publications, Aroa’s products have been used in more than four million procedures to date, with distribution into its key market of the United States by Appulse and Tela Bio. Founded in 2008, Aroa is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX:ARX). www.aroabio.com/

ontacts
Investor Simon Hinsley Investor Relations [email protected] + 61 401 809 653	Media Australia Matthew Wright [email protected] +61 451 896 420	New Zealand Piet De Jong [email protected]
		+64 21 812 766